Momcozy Showcases FDA-Certified Innovations for Mothers and Babies at Medtrade 2025
Medtrade is the largest home medical equipment (HME) trade show and conference in the United States. It serves as a pivotal stage for industry leaders, manufacturers, and providers to present the latest advancements in mobility, respiratory care, sleep solutions, rehabilitation, and daily living aids.
Momcozy has already built a strong global presence, serving over 3 million mothers across 60+ countries. Showcasing its FDA-certified products at Medtrade solidifies its reputation as a professional and trustworthy brand in the home medical equipment industry, aligning it with the highest safety and quality standards.
Momcozy at Medtrade: Showcasing Innovation to Professionals
At Medtrade 2025, Momcozy's booth attracted significant attention from many professionals, including healthcare providers, medical equipment distributors, and retailers. Attendees had the opportunity to explore the brand's cutting-edge maternity and baby care solutions, gaining a deeper understanding of its products.
Many professionals praised Momcozy's innovative approach and thoughtful design, recognizing the brand's commitment to enhancing comfort, efficiency, and safety for mothers and babies. The event provided a valuable platform for meaningful discussions on the future of maternal care technology and its role in improving the parenting experience.
Cutting-Edge Innovations for Mothers and Babies
Momcozy showcased its award-winning breast pumps, maternity essentials, and baby care products at Medtrade 2025, all designed to provide comfort, efficiency, and convenience for modern mothers. Highlights included the Mobile Style™ Hands-Free Breast Pump, offering powerful yet discreet suction for seamless multitasking, and the V1 Pro Hospital-Grade Wearable Breast Pump, delivering hospital-grade performance with customizable suction levels. S12 Pro Hands-Free Breast Pump stood out for its ergonomic double-sealed flange, ensuring a snug fit and leak prevention. Beyond pumping solutions, Ergonest Maternity Belly Band provided tailored support for expectant mothers, while the Baby 2-in-1 Nasal Aspirator with Sprayer made infant nasal care effortless with its dual-function design. These innovative products reaffirm Momcozy's commitment to enhancing the motherhood journey with smart, user-friendly solutions.
About Momcozy:
Founded in 2018, Momcozy provides a one-stop solution for moms and babies worldwide, supporting women from pregnancy to early motherhood. Comfort, for mothers and babies is always their top priority. Momcozy is available on multiple platforms, both online and in stores, and offers a comprehensive range of products. For more Information, visit www.momcozy.com.
Contact Info:
Name: Phoebe Xiao
Email: Send Email
Organization: Momcozy
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Former FDA chief: Ultraprocessed foods are ‘addictive' like drugs
(NewsNation) — Ultraprocessed foods engineered with fat, sugar and salt are 'addictive' and driving America's obesity crisis, according to a former Food and Drug Administration commissioner who argues the problem goes far beyond individual willpower. Dr. David Kessler, who led the FDA and later ran Operation Warp Speed, said obesity rates have jumped from 13% in the 1960s to 42% today because of what he calls 'ultraformulated foods' that trigger dopamine responses similar to addictive drugs. 'We took fat, sugar and salt, put it on every corner, made it available 24/7, made it socially acceptable to eat any time,' Kessler said Thursday on NewsNation's 'Elizabeth Vargas Reports.' 'We're living in a food carnival. What did we expect to happen?' Air pollution, herbal remedies tied to lung cancer risk: Study Four out of 10 American adults are classified as obese, with up to a quarter of them morbidly obese. Kessler, author of the new book 'Diet, Drugs and Dopamine,' said the real health threat comes from toxic abdominal fat that infiltrates the liver, pancreas and heart. Around 25% of American men will develop heart failure in their lifetime, 33% will develop diabetes, and 25% will have a stroke, according to Kessler. Unlike traditional processed foods that contain preservatives or stabilizers, ultraformulated foods combine fat, sugar and salt in ways that affect the brain's reward systems, Kessler explained. Food companies design products to hit what they call the 'bliss point' that triggers these reward circuits. Fact check: Are there 1.4M illegal immigrants on Medicaid? 'It's not like amphetamine or cocaine, but I certainly use food,' said Kessler, who gained 40 pounds after running Operation Warp Speed. 'It's not about willpower. It's about biology.' The former FDA chief said Americans need to change how they view these foods, comparing the effort to the successful campaign against tobacco that transformed cigarettes from glamorous to deadly in public perception. Kessler also weighed in on GLP-1 drugs like Ozempic, which federal researchers are now studying for use to treat alcohol addiction in patients not overweight. These medications work by slowing food through the stomach to the point of nausea, counterbalancing reward circuits, though Kessler said more research is needed. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Time Business News
3 hours ago
- Time Business News
The Science Behind Recovery in Accredited Addiction Treatment Centers
Accredited addiction treatment centers function within a rigorously structured framework that upholds both safety and efficacy. Accreditation is granted by recognized bodies such as CARF (Commission on Accreditation of Rehabilitation Facilities) or The Joint Commission, which ensures adherence to strict clinical standards. These institutions are required to follow evidence-informed protocols, maintain licensed medical staff, and continuously evaluate treatment outcomes. This foundational integrity not only enhances credibility but ensures that clients receive care rooted in scientific rigor. Accreditation acts as a protective mechanism—safeguarding the quality of intervention throughout a patient's journey toward sobriety. When taking medications that influence the brain and body, it's essential to know how long their effects may linger. One such medication, used to manage opioid dependence, remains detectable in the body for varying durations depending on several factors. How Long does suboxone stay in your system depends on the dosage, metabolism, liver function, and frequency of use. On average, its primary component, buprenorphine, can be detected in urine for up to 7–10 days. However, traces may persist longer in hair or blood. Awareness of these timelines can aid in treatment planning and ensure safe, informed recovery decisions. Addiction is not a moral failing; it is a neurological hijacking. Chronic substance use fundamentally rewires the brain, particularly areas responsible for reward, impulse control, and emotional regulation. Dopaminergic surges create a feedback loop that distorts natural reward pathways, often rendering daily pleasures obsolete. However, the brain retains an extraordinary ability—neuroplasticity. During recovery, with sustained abstinence and therapeutic intervention, neural circuits begin to recalibrate. This slow but measurable restoration underpins the physiological basis of long-term recovery. Accredited centers harness this science to structure timelines and therapies that support biological healing. The arsenal of treatment strategies deployed in accredited centers is backed by empirical research and clinical validation. Cognitive Behavioral Therapy (CBT), for instance, is proven to restructure maladaptive thought patterns that often fuel substance abuse. Medication-Assisted Treatment (MAT), using FDA-approved drugs like buprenorphine or naltrexone, addresses both withdrawal symptoms and cravings with biochemical precision. More recently, modalities such as Eye Movement Desensitization and Reprocessing (EMDR) and biofeedback have emerged with strong neuroscientific endorsements. The underlying principle across these therapies is consistency with data—interventions are only used if they withstand rigorous peer-reviewed scrutiny. Many individuals grappling with addiction concurrently suffer from psychiatric conditions such as depression, PTSD, or bipolar disorder. This phenomenon, known as dual diagnosis, complicates recovery if left unaddressed. Accredited centers prioritize integrated care models that simultaneously treat substance use and mental health disorders. Clinical staff are trained to identify overlapping symptoms and deploy multidisciplinary approaches, combining psychiatry, psychotherapy, and pharmacology. The science is clear: treating both conditions in tandem leads to significantly higher recovery rates, preventing relapse born from untreated psychological triggers. Recovery is not a solitary expedition—it's a communal journey. Group therapy sessions, peer support communities like 12-Step programs, and structured social interactions offer critical emotional scaffolding. Neuroscience confirms that oxytocin release during empathetic social encounters can modulate stress responses, aiding in relapse prevention. Family therapy also plays a vital role by reconstructing fractured relational ecosystems and improving communication patterns. These psychosocial mechanisms, when embedded in a scientific treatment plan, amplify resilience and elevate recovery prospects. Data is the backbone of modern addiction treatment. Accredited centers employ advanced outcome-tracking tools to personalize and recalibrate treatment plans. From biometric monitoring to standardized psychological assessments, progress is meticulously documented. Longitudinal studies, often conducted in collaboration with academic institutions, inform best practices and fuel innovation. These research initiatives uncover new biomarkers, refine predictive models for relapse, and explore genetic predispositions to addiction—transforming treatment from reactive to proactive. Accredited addiction treatment centers represent the confluence of empirical science and human empathy. Their methodologies are steeped in neurobiological understanding, evidence-based therapies, and continuous innovation. Yet, beyond the science lies a fundamental ethos—compassion. By aligning clinical excellence with individualized care, these centers don't just treat addiction; they restore dignity, purpose, and the innate human capacity for transformation. TIME BUSINESS NEWS
Yahoo
3 hours ago
- Yahoo
Why Moderna Stock Was So Healthy This Week
The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. This might not be enough to turn around the fortunes of the developer of go-to COVID-19 vaccine Spikevax, however. 10 stocks we like better than Moderna › Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing the Spikevax coronavirus vaccine, was an uncharacteristically popular stock. Investors piled into its shares over the week, sending it to a more than 12% gain over the period, according to data compiled by S&P Global Market Intelligence. Positive news from the lab was a significant factor in this. On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical trial the vaccine, developed using Moderna's signature mRNA-based approach, produced a more robust immune response than a standard flu jab currently available on the market. That surely came as a relief to Moderna investors, since the company's latest stock-rattling news was its withdrawal of a Food and Drug Administration application for a combination COVID-19/flu vaccine in May. At the time, the company pledged to submit a new application based on efficacy data from the stand-alone trial. Along with the latest findings for mRNA-1010, Moderna said that it would also resubmit its application for the combination vaccine. As for the flu shot alone, in the press release detailing the trial's results the company quoted CEO Stéphane Bancel as saying that they "are a significant milestone in our effort to reduce the burden of influenza in older adults." Although this latest development is the good news Moderna shareholders have been waiting for quite some time to receive, I personally don't think it makes the company's stock a buy in and of itself, as I can't imagine a new flu vaccine will light the world on fire. Having said that, Moderna does have an admirably loaded slate of development programs, so if one or several show promise the shares might become more enticing. Before you buy stock in Moderna, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Moderna wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. Why Moderna Stock Was So Healthy This Week was originally published by The Motley Fool
